BTIG Research Forecasts Strong Price Appreciation for Edwards Lifesciences (NYSE:EW) Stock

Edwards Lifesciences (NYSE:EW) had its price target hoisted by equities research analysts at BTIG Research from $110.00 to $115.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. BTIG Research‘s price objective indicates a potential upside of 15.71% from the stock’s previous close.

EW has been the topic of several other research reports. Argus boosted their target price on Edwards Lifesciences from $105.00 to $115.00 and gave the company a “buy” rating in a research note on Friday, August 21st. UBS Group reaffirmed a “buy” rating and set a $110.00 price target (up from $90.00) on shares of Edwards Lifesciences in a research report on Thursday, October 8th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Rothschild & Co Redburn increased their price objective on Edwards Lifesciences from $99.00 to $102.00 and gave the company a “buy” rating in a report on Monday, July 27th. Finally, Barclays raised shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, October 7th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $104.08.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $99.39 on Thursday. The stock has a market cap of $57.23 billion, a price-to-earnings ratio of 57.12, a P/E/G ratio of 2.49 and a beta of 0.85. Edwards Lifesciences has a 12-month low of $74.66 and a 12-month high of $100.25. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $88.48 and its 200 day simple moving average is $85.61.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, November 4th. The medical research company reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.06. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.72 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the firm earned $0.67 EPS. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. As a group, research analysts anticipate that Edwards Lifesciences will post 3.00 earnings per share for the current year.

Insiders Place Their Bets

In related news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction dated Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 5,045 shares of company stock worth $451,596 in the last 90 days. Company insiders own 0.31% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $1,274,082,000. Bank of America Corp DE bought a new stake in Edwards Lifesciences during the second quarter valued at $605,397,000. Deutsche Bank AG bought a new stake in Edwards Lifesciences in the second quarter worth approximately $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Edwards Lifesciences by 0.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after buying an additional 30,495 shares during the period. Institutional investors own 79.46% of the company’s stock.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards reported third-quarter adjusted EPS of $0.80, topping the $0.74 consensus, and revenue of $1.72 billion versus expectations of $1.68 billion. Revenue grew year over year, while the company raised its full-year outlook and narrowed its 2026 forecast range. Q3 earnings, revenue and outlook
• Positive Sentiment: Truist Financial upgraded EW from “hold” to “strong-buy,” adding analyst support. Truist upgrade
• Positive Sentiment: Management highlighted strong momentum in its transcatheter mitral and tricuspid therapies business, with TMTT sales up 44%. Separately, trial results for the PASCAL tricuspid repair system showed better outcomes than medical therapy through one year, supporting the product’s potential. Q3 results and TMTT growth PASCAL trial results
• Negative Sentiment: CEO commentary acknowledged that more TAVR competition is coming, which could pressure Edwards’ position in a key market. RBC also said the Progress trial data is unlikely to meaningfully expand the transcatheter market, limiting the potential upside from that study. TAVR competition RBC assessment of Progress trial

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease and critical care. The company develops and manufactures products designed to treat conditions affecting the heart’s valves, including aortic, mitral and tricuspid valve disorders.

Its portfolio includes transcatheter aortic valve replacement systems, transcatheter mitral and tricuspid therapies, surgical heart valves and valve-repair technologies. Edwards also provides related delivery systems and other medical devices used by physicians in minimally invasive and open-heart procedures.

Founded in 1958 by Miles Lowell Edwards, the company is headquartered in Irvine, California, and serves healthcare providers and patients internationally.